We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism.
- Authors
Cheng, W.-F.; Chang, M.-C.; Sun, W.-Z.; Lee, C.-N.; Lin, H.-W.; Su, Y.-N.; Hsieh, C.-Y.; Chen, C.-A.
- Abstract
A novel method for generating an antigen-specific cancer vaccine and immunotherapy has emerged using a DNA vaccine. However, antigen-presenting cells (APCs) have a limited life span, which hinders their long-term ability to prime antigen-specific T cells. Connective tissue growth factor (CTGF) has a role in cell survival. This study explored the intradermal administration of DNA encoding CTGF with a model tumor antigen, human papilloma virus type 16 E7. Mice vaccinated with CTGF/E7 DNA exhibited a dramatic increase in E7-specific CD4+ and CD8+ T-cell precursors. They also showed an impressive antitumor effect against E7-expressing tumors compared with mice vaccinated with the wild-type E7 DNA. The delivery of DNA encoding CTGF and E7 or CTGF alone could prolong the survival of transduced dendritic cells (DCs) in vivo. In addition, CTGF/E7-transduced DCs could enhance a higher number of E7-specific CD8+ T cells than E7-transduced DCs. By prolonging the survival of APCs, DNA vaccine encoding CTGF linked to a tumor antigen represents an innovative approach to enhance DNA vaccine potency and holds promise for cancer prophylaxis and immunotherapy.Gene Therapy (2008) 15, 1007–1016; doi:10.1038/gt.2008.25; published online 20 March 2008
- Subjects
ANTIGENS; CANCER treatment; THERAPEUTICS; IMMUNOTHERAPY; T cells; DNA; PAPILLOMAVIRUS diseases; DENDRITIC cells; ANTIGEN presenting cells
- Publication
Gene Therapy, 2008, Vol 15, Issue 13, p1007
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2008.25